Neil Archer

First employee OUS for a commercial stage biotech in the treatment of MASH. Built out a regional hub in Switzerland, hired affiliate teams in European markets and defined go-to-market strategies globally. Sits on Executive Leadership Team and contributes to enterprise strategy.

Member of the supervisory board of Adrenomed, a clinical stage biotech developing a candidate for the treatment of sepsis.

• Led the integration of Celgene and Bristol Myers Squibb affiliates in Germany, creating a new organisation with revenues in excess of $3B and 1,200+ employees
• Oversaw multiple launches ranging from small molecules to personalised cell therapies
• Drove continuous structural, capability and P&L enhancements reflecting evolving company portfolio
• Heavily engaged at governmental level with environment shaping efforts through economic crisis and changing attitudes towards biopharma in Germany.

• Leadership of Celgene's second largest affiliate worldwide in terms of sales approx $1B
• Challenging brief to maximise performance of current portfolio whilst bringing about the cultural and organizational change required to embrace multiple launches and LoE events in coming years.

• Leadership of fifteen countries across CEE with regional P&L accountability
• Direct reports include affiliate general managers and regional functional leaders
• Commercial activities spanned EU and non-EU markets at all lifecycle phases against the challenging backdrop that this geography entails.

• Above-country marketing leadership of Eli Lilly's then largest portfolio of neuroscience brands
• Deliverables included oversight of commercial efforts for marketed assets in depression, ADHD and Alzheimer's disease diagnostics, market preparation for two Alzheimer's drug candidates and business development activities.

• Leadership of $260M business
• Delivery of P&L targets across Sweden, Denmark, Norway and Iceland
• Turnaround of initially flagging performance achieved
• Active contributions to local trading environment through board membership of trade association and hands-on involvement in government relations activities

• Leadership of $100M business with above-target P&L delivery
• Turnaround of operational and people-related crises achieved, leaving an engaged, motivated and successful affiliate as a legacy.

• Successfully engineered and implemented new operating structures across a highly diverse geographic and cultural landscape
• Strong organizational acumen demonstrated through leadership of the functional merger of eight originally independent affiliates into a single cluster in Middle East & North Africa

• Successful leadership of UK affiliate's largest franchise
• In-market brands included Zyprexa and Prozac with launches involving Cymbalta and Strattera.

• Preparations across region for Prozac's loss of exclusivity and launch preparations of Cymbalta.

• Commercial leadership of complex retail and tender business across eight Caribbean islands.